(taken directly from the application) There are several requirements which must be met before replication deficient adenovirus can be considered a viable vehicle for the delivery of genes into the brain parenchyma for correction of inherited disorders of metabolism. First, the adenovirus must be capable of infecting multiple cell types relatively efficiently. Second, transgene expression must occur in the infected cells and it must persist a reasonable period of time. Third, the adenovirus must be capable of infecting a large proportion of the brain for generalized correction. Because our laboratory and others have already demonstrated the ability of adenovirus to satisfy the first requirement, it is the purpose of this proposal to develop methods which will satisfy the latter two; namely, the problems associated with persistence and delivery. We hypothesize that i) persistence of adenoviral gene expression can be improved by altering the production of endogenous viral proteins through vector sequence manipulation and/or administration of exogenous immunosuppressive cytokines at the time of adenoviral infections, and ii) delivery techniques can be developed that permit infection of a large portion of the CNS either through blood-brain barrier disruption or improved intraventricular and parenchymal delivery schemes. Although the long term goal of these studies is aimed at the treatment of neurologic manifestations of inherited disease, these vectors should be generally useful in transferring genes to other affected tissues. In addition, the techniques that will be developed for global delivery of adenovirus in the CNS should be applicable to other vectors.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS034568-01
Application #
2273839
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Project Start
1995-02-14
Project End
1999-01-31
Budget Start
1995-02-14
Budget End
1996-01-31
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Iowa
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041294109
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Tecedor, Luis; Stein, Colleen S; Schultz, Mark L et al. (2013) CLN3 loss disturbs membrane microdomain properties and protein transport in brain endothelial cells. J Neurosci 33:18065-79
Benraiss, Abdellatif; Toner, Michael J; Xu, Qiwu et al. (2013) Sustained mobilization of endogenous neural progenitors delays disease progression in a transgenic model of Huntington's disease. Cell Stem Cell 12:787-99
Hudry, Eloise; Dashkoff, Jonathan; Roe, Alysson D et al. (2013) Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med 5:212ra161
Chen, Yong Hong; Claflin, Kristin; Geoghegan, James C et al. (2012) Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease. Mol Ther 20:1393-9
Schultz, Mark L; Tecedor, Luis; Chang, Michael et al. (2011) Clarifying lysosomal storage diseases. Trends Neurosci 34:401-10
Chen, Yong Hong; Chang, Michael; Davidson, Beverly L (2009) Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med 15:1215-8
Chang, Michael; Cooper, Jonathan D; Sleat, David E et al. (2008) Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther 16:649-56
Cabrera-Salazar, Mario A; Roskelley, Eric M; Bu, Jie et al. (2007) Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease. Mol Ther 15:1782-8
Sands, Mark S; Davidson, Beverly L (2006) Gene therapy for lysosomal storage diseases. Mol Ther 13:839-49
Kang, Yubin; Xie, Litao; Tran, Diane Thi et al. (2005) Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Blood 106:1552-8

Showing the most recent 10 out of 33 publications